Oxygen-15 positron-emission tomography for predicting selective delivery of a chemotherapeutic agent to hepatic cancers during angiotensin II-induced hypertension

被引:12
作者
Koh, T
Taniguchi, H
Yamagishi, H
机构
[1] Kyoto Prefectural Univ Med, Dept Digest Surg, Kamigyou Ku, Kyoto 6028566, Japan
[2] Kyoto Prefectural Yosanoumi Hosp, Dept Surg, Kyoto, Japan
关键词
anglotensin II; hypertension chemotherapy; metastatic liver cancer; hepatocellular carcinoma; positron emission tomography;
D O I
10.1007/s00280-003-0575-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Selective drug delivery is important for successful chemotherapy. In patients with hepatic cancer, we used O-15-carbon dioxide (steady-state) and O-15-water (dynamic) positron emission tomography (PET) to evaluate changes in blood flow induced by angiotensin (AT) 11 in the liver parenchyma, hepatic tumors, and spleen. Methods: The study group comprised) patients, 6 with hepatic metastasis and 7 with hepatocellular carcinoma. PET was performed before and during, AT 11 administration to induce hypertension. Results: Steady-state PET images showed a preferential increase in blood flow to hepatic tumor compared with liver parenchyma during hypertension. In dynamic PET, tumor blood flow was maintained during induced hypertension while hepatic arterial blood flow, portal blood flow, total hepatic blood flow, and splenic blood flow decreased to 71.4% (not significant), 65% (P<0.01), 67.2% (P<0.001), and 72.3% (P<0.01) of the respective baseline values. Conclusion: AT II-induced hypertension produced a relative increase in tumor blood flow. Oxygen-15 PET should be useful for predicting preferential drug delivery to hepatic cancers.
引用
收藏
页码:349 / 358
页数:10
相关论文
共 25 条
[1]   62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases [J].
Flower, MA ;
Zweit, J ;
Hall, AD ;
Burke, D ;
Davies, MM ;
Dworkin, MJ ;
Young, HE ;
Mundy, J ;
Ott, RJ ;
McCready, VR ;
Carnochan, P ;
Allen-Mersh, TG .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (01) :99-103
[2]   REGIONAL CHEMOTHERAPY FOR COLORECTAL LIVER METASTASES - A PHASE-II EVALUATION OF TARGETED HEPATIC ARTERIAL 5-FLUOROURACIL FOR COLORECTAL LIVER METASTASES [J].
GOLDBERG, JA ;
KERR, DJ ;
WILMOTT, N ;
MCKILLOP, JH ;
MCARDLE, CS .
BRITISH JOURNAL OF SURGERY, 1990, 77 (11) :1238-1240
[3]   THE EFFECTS OF VASOPRESSIN INFUSION ON HEPATIC HEMODYNAMICS IN AN EXPERIMENTAL-MODEL OF LIVER METASTASES [J].
HEMINGWAY, DM ;
CHANG, D ;
COOKE, TG ;
JENKINS, SA .
BRITISH JOURNAL OF CANCER, 1991, 64 (02) :212-214
[4]   FLUCTUATIONS IN TUMOR BLOOD-FLOW UNDER NORMOTENSION AND THE EFFECT OF ANTIOTENSIN-II-INDUCED HYPERTENSION [J].
HORI, K ;
SUZUKI, M ;
TANDA, S ;
SAITO, S ;
SHINOZAKI, M ;
ZHANG, QH .
JAPANESE JOURNAL OF CANCER RESEARCH, 1991, 82 (11) :1309-1316
[5]   SYMPOSIUM ON RECENT PROGRESS IN CHEMOTHERAPY OF LEUKEMIA .6. ANGIOTENSIN-II-INDUCED HYPERTENSION CHEMOTHERAPY (IHC) FOR ADVANCED GASTROINTESTINAL, PANCREATIC AND HEPATOBILIARY CARCINOMA [J].
HOSHI, M ;
SATO, H .
INTERNAL MEDICINE, 1995, 34 (04) :298-299
[6]  
KEMENY N, 1980, CANCER-AM CANCER SOC, V45, P876, DOI 10.1002/1097-0142(19800301)45:5<876::AID-CNCR2820450509>3.0.CO
[7]  
2-X
[8]   Systemic therapy for hepatocellular carcinoma [J].
Leung, TWT ;
Johnson, PJ .
SEMINARS IN ONCOLOGY, 2001, 28 (05) :514-520
[9]  
NELDER JA, 1965, COMPUT J, V17, P443
[10]  
ONOHARA S, 1988, ACTA RADIOL, V29, P197